Protocol Ledger

NCT04743141 · Phase III · RECRUITING

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Interventional Phase III clinical trial protocol NCT04743141 sponsored by Pfizer in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-28 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04743141
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04743141
Protocol FieldVerified Registry Value
NCT IdentifierNCT04743141
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2021-04-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04743141
Hospital Research SiteLocationSite Profile
Advanced Research Center, Inc.Anaheim, CAOpen Hospital Dossier ->
ProScience Research GroupCulver City, CAOpen Hospital Dossier ->
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI